HUE026820T2 - The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders - Google Patents
The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders Download PDFInfo
- Publication number
- HUE026820T2 HUE026820T2 HUE07804842A HUE07804842A HUE026820T2 HU E026820 T2 HUE026820 T2 HU E026820T2 HU E07804842 A HUE07804842 A HU E07804842A HU E07804842 A HUE07804842 A HU E07804842A HU E026820 T2 HUE026820 T2 HU E026820T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- compounds
- cell
- treatment
- ppg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79910306P | 2006-05-09 | 2006-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE026820T2 true HUE026820T2 (en) | 2016-07-28 |
Family
ID=38668152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE07804842A HUE026820T2 (en) | 2006-05-09 | 2007-05-09 | The use of Syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20090306214A1 (enExample) |
| EP (1) | EP2026775B1 (enExample) |
| JP (1) | JP5225264B2 (enExample) |
| AU (1) | AU2007246779B2 (enExample) |
| CA (1) | CA2651375C (enExample) |
| DK (1) | DK2026775T3 (enExample) |
| ES (1) | ES2542344T3 (enExample) |
| HU (1) | HUE026820T2 (enExample) |
| IL (1) | IL195152A (enExample) |
| PL (1) | PL2026775T3 (enExample) |
| PT (1) | PT2026775E (enExample) |
| WO (1) | WO2007129226A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031129A2 (en) * | 2002-10-03 | 2004-04-15 | New Era Biotech, Ltd. | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| CA2560922C (en) * | 2004-03-26 | 2014-01-07 | New Era Biotech, Ltd. | Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions |
| GB0804213D0 (en) * | 2008-03-06 | 2008-04-16 | New Era Biotech Ltd | A method of printing or preventing pain |
| US8802734B2 (en) * | 2009-09-09 | 2014-08-12 | Novaremed Limited | Method of treating or preventing pain |
| JP2013504555A (ja) * | 2009-09-09 | 2013-02-07 | ノヴァレメッド リミテッド | 疼痛の治療又は予防方法 |
| DK2914296T4 (da) | 2012-11-01 | 2022-01-03 | Infinity Pharmaceuticals Inc | Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer |
| EP2970194A1 (en) | 2013-03-15 | 2016-01-20 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| SG10201709926VA (en) | 2013-05-30 | 2017-12-28 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| JP6466924B2 (ja) | 2013-10-04 | 2019-02-06 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN113620958A (zh) | 2014-03-19 | 2021-11-09 | 无限药品股份有限公司 | 用于治疗PI3K-γ介导的障碍的杂环化合物 |
| WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| KR102787845B1 (ko) | 2015-09-14 | 2025-03-31 | 트웰브 테라퓨틱스, 아이엔씨. | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG11201811237WA (en) | 2016-06-24 | 2019-01-30 | Infinity Pharmaceuticals Inc | Combination therapies |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1908322A (en) * | 1932-04-07 | 1933-05-09 | Claude R Cook | Weed puller |
| US2908691A (en) * | 1958-07-14 | 1959-10-13 | Searle & Co | Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| WO2004031129A2 (en) * | 2002-10-03 | 2004-04-15 | New Era Biotech, Ltd. | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| CA2560922C (en) * | 2004-03-26 | 2014-01-07 | New Era Biotech, Ltd. | Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions |
-
2007
- 2007-05-09 AU AU2007246779A patent/AU2007246779B2/en not_active Ceased
- 2007-05-09 PL PL07804842T patent/PL2026775T3/pl unknown
- 2007-05-09 ES ES07804842.8T patent/ES2542344T3/es active Active
- 2007-05-09 CA CA2651375A patent/CA2651375C/en not_active Expired - Fee Related
- 2007-05-09 JP JP2009508544A patent/JP5225264B2/ja not_active Expired - Fee Related
- 2007-05-09 WO PCT/IB2007/002471 patent/WO2007129226A2/en not_active Ceased
- 2007-05-09 PT PT78048428T patent/PT2026775E/pt unknown
- 2007-05-09 EP EP07804842.8A patent/EP2026775B1/en not_active Not-in-force
- 2007-05-09 HU HUE07804842A patent/HUE026820T2/en unknown
- 2007-05-09 DK DK07804842.8T patent/DK2026775T3/en active
- 2007-05-09 US US12/227,104 patent/US20090306214A1/en not_active Abandoned
-
2008
- 2008-11-06 IL IL195152A patent/IL195152A/en active IP Right Grant
-
2012
- 2012-01-06 US US13/344,976 patent/US20120108666A1/en not_active Abandoned
-
2013
- 2013-10-09 US US14/049,454 patent/US20140039060A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120108666A1 (en) | 2012-05-03 |
| JP5225264B2 (ja) | 2013-07-03 |
| EP2026775A2 (en) | 2009-02-25 |
| WO2007129226A3 (en) | 2008-05-08 |
| PT2026775E (pt) | 2015-08-05 |
| AU2007246779B2 (en) | 2013-11-28 |
| JP2009536191A (ja) | 2009-10-08 |
| US20140039060A1 (en) | 2014-02-06 |
| IL195152A0 (en) | 2009-09-22 |
| IL195152A (en) | 2015-10-29 |
| WO2007129226A2 (en) | 2007-11-15 |
| PL2026775T3 (pl) | 2015-12-31 |
| US20090306214A1 (en) | 2009-12-10 |
| AU2007246779A1 (en) | 2007-11-15 |
| CA2651375C (en) | 2015-12-22 |
| EP2026775B1 (en) | 2015-04-29 |
| DK2026775T3 (en) | 2015-06-29 |
| CA2651375A1 (en) | 2007-11-15 |
| ES2542344T3 (es) | 2015-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2026775T3 (en) | USE OF SYK tyrosine kinase inhibitors for treating cell proliferative DISORDERS | |
| JPH07228558A (ja) | スチルベン誘導体及びそれを含有する制癌剤 | |
| KR20050059094A (ko) | 4-플루오로-2-시아노피롤리딘 유도체 벤젠술폰산염 | |
| JP6758669B2 (ja) | アスコクロリン誘導体およびａｍｐｋ活性化剤としてのその使用 | |
| WO2023141852A1 (zh) | Cdk2抑制剂及其制备方法和用途 | |
| EP1750691B1 (en) | Compounds for treatment of aids and other diseases | |
| EP0781552A1 (en) | Multidrug resistance inhibitors | |
| CA2368733C (en) | Phenylalanine derivatives | |
| US7572778B2 (en) | Fluorocombretastatin and derivatives thereof | |
| JPH024748A (ja) | 薬理作用を有するペプチド類 | |
| JP7734361B2 (ja) | 化合物又はその塩及びその製造方法、化合物又はその塩を含む医薬品組成物及びその製造方法 | |
| CN103450164B (zh) | 格尔德霉素衍生物及其制备方法和用途 | |
| WO1994008947A1 (fr) | Nouveau derive aminoacide | |
| HK1161872A (en) | New retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties |